<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082407</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-MC-GWAD</org_study_id>
    <nct_id>NCT00082407</nct_id>
  </id_info>
  <brief_title>Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin</brief_title>
  <official_title>Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect
      of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as
      measured by hemoglobin A1c (HbA1c).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glcosylated Hemoglobin (HbA1c)</measure>
    <time_frame>baseline, week 52</time_frame>
    <description>Change in HbA1c from baseline to week 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c &lt;=7%</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of patients in each arm who had HbA1c &gt;7% at baseline and had HbA1c &lt;=7% at week 52 (percentage = [number of subjects with HbA1c &lt;=7% at week 52 divided by number of subjects with HbA1c &gt;7% at baseline] * 100%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline, week 52</time_frame>
    <description>Change in body weight from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Glucose</measure>
    <time_frame>baseline, week 52</time_frame>
    <description>Change in fasting serum glucose from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 7-point Self-monitored Blood Glucose (SMBG) Profile</measure>
    <time_frame>baseline, week 52</time_frame>
    <description>Change in 7-point (pre-breakfast, after breakfast, pre-lunch, after lunch, pre-dinner, after dinner, 0300 hours) SMBG profile from baseline to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Hypoglycemic Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study divided by the total number of patients who particiapted in the 52 week Parent Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rate of Hypoglycemic Events</measure>
    <time_frame>baseline, week 52</time_frame>
    <description>Change in rate of hypoglycemic events per 30 days per patient from baseline to week 52</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">505</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Exenatide Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biphasic Insulin Aspart Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
    <arm_group_label>Exenatide Arm</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart</intervention_name>
    <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
    <arm_group_label>Biphasic Insulin Aspart Arm</arm_group_label>
    <other_name>NovoLog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have been treated with a stable dose of the following for at least 3 months
             prior to screening: 1. &gt;=1500 mg/day immediate-release metformin or extended-release
             metformin and at least an optimally effective dose for brand of sulfonylurea, or 2. a
             fixed-dose sulfonylurea/metformin combination therapy with the same sulfonylurea and
             metformin requirements as for the individual components

          -  HbA1c between 7.0% and 11.0%, inclusive.

          -  Patients have a body mass index &gt;25kg/m2 and &lt;40 kg/m2.

          -  Female patients are not breastfeeding, and female patients of childbearing potential
             test negative for pregnancy, do not intend to become pregnant during the study, and
             agree to continue using a reliable method of birth control

        Exclusion Criteria:

          -  Patients are investigator site personnel directly affiliated with the study, or are
             immediate family of investigator site personnel directly affiliated with the study.

          -  Patients are employed by Lilly or Amylin.

          -  Patients have previously, in this or any other study, received exenatide or
             glucagon-like peptide-1 analogs.

          -  Patients have participated in an interventional medical, surgical, or pharmaceutical
             study within 30 days prior to screening. This criterion includes drugs that have not
             received regulatory approval for any indication at the time of study entry.

          -  Patients have had greater than three episodes of severe hypoglycemia within 6 months
             prior to screening.

          -  Patients have less than 5 years of remission history from any malignancy (other than
             basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ
             prostate cancer).

          -  Patients have cardiac disease that is Class III or IV, according to the New York Heart
             Association criteria.

          -  Patients have a known allergy or hypersensitivity to biphasic insulin aspart,
             exenatide, or excipients contained in these agents.

          -  Patients have characteristics contraindicating metformin or sulfonylurea use,
             according to product-specific label.

          -  Patients have a history of renal transplantation or are currently receiving renal
             dialysis or have serum creatinine &gt;=1.5 mg/dL for males and &gt;=1.2 mg/dL for females.

          -  Patients have obvious clinical signs or symptoms of liver disease, acute or chronic
             hepatitis, or alanine aminotransferase/serum glutamic pyruvic transaminase greater
             than three times the upper limit of the reference range.

          -  Patients have known hemoglobinopathy or chronic anemia.

          -  Patients have active proliferative retinopathy or macular edema.

          -  Patients are receiving treatment for gastrointestinal disease with a drug directly
             affecting gastrointestinal motility, including but not limited to metoclopramide,
             cisapride, and chronic macrolide antibiotics.

          -  Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid
             therapy (excluding topical and inhaled preparations) or have received such therapy
             within 2 weeks immediately prior to screening.

          -  Patients have used any prescription drug to promote weight loss within 3 months prior
             to screening.

          -  Patients have been treated for longer than 2 weeks with any of the following excluded
             medications within 3 months prior to screening: insulin, thiazolidinediones,
             alpha-glucosidase inhibitors, meglitinides.

          -  Patients have any other condition (including known drug or alcohol abuse or
             psychiatric disorder) that precludes them from following and completing the protocol,
             in the opinion of the investigator.

          -  Patients fail to satisfy the investigator of suitability to participate for any other
             reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinica bolnica Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb-Rebro</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bolnica &quot;Sveti Duh&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Karlheinz Hehemann</name>
      <address>
        <city>Beckum</city>
        <zip>59269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Klaus Busch</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Clinic and Policlinic 3</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKFE GmbH</name>
      <address>
        <city>Mainz</city>
        <zip>55119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut for diabetic research</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil, Institut fur Stoffwechselstorungen</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Thomas Behnke</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bernd Donaubauer</name>
      <address>
        <city>Oschatz</city>
        <zip>04758</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabruck</name>
      <address>
        <city>Osnabruck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Joerg Steindorf</name>
      <address>
        <city>Schkeuditz</city>
        <zip>04435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jerzi Jasinski</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Polyclinic&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>10552</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Internal Medicine Department &quot;Papagergiou&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto di Endocrinologia</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di fisiopatologia clinica</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Medicina Generale</name>
      <address>
        <city>Milan</city>
        <zip>60-20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Univarsitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Universita di Malattie del Metabolismo e Diabetologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7300 DS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum Location Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-076</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santo Andre</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Protectora dos Diabeticos de Portugal</name>
      <address>
        <city>Lisboa</city>
        <zip>1250-203</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4454-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Diabet</name>
      <address>
        <city>Bucuresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic nr. 1 Judetean</name>
      <address>
        <city>Judet Timis</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Endocrinology Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setchenov Moscow Medical Academy</name>
      <address>
        <city>Moscow</city>
        <zip>119881</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Stomatological</name>
      <address>
        <city>Moscow</city>
        <zip>123448</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Medical Academy for Advanced Medical Studies, Ministry of Health</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of St. Elizabeth's</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #2</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Military Academy</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitetni klinicni center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splosna bolnisnica Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vega Baja</name>
      <address>
        <city>Alicante</city>
        <zip>03300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Service (Planta Baja)</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Teruel</name>
      <address>
        <city>Teruel</city>
        <zip>44002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Ribera Alzira</name>
      <address>
        <city>Valencia</city>
        <zip>46600 Alzira</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran General Hospital-Taichung</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research, Ward 34, Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Unit, Blackburn Royal Infirmary</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 3LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9YW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Michael White Center for Diabetes and Endocrinology</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Sciences Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Education Centre, James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Labs, Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Trial Unit OCDEM, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Unit, Gladsone Centre, Maelor Hospital</name>
      <address>
        <city>Wrexham</city>
        <zip>LL13 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007 Feb;50(2):259-67. Epub 2006 Dec 8.</citation>
    <PMID>17160407</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2004</study_first_submitted>
  <study_first_submitted_qc>May 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2004</study_first_posted>
  <results_first_submitted>July 16, 2009</results_first_submitted>
  <results_first_submitted_qc>June 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2013</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exendin</keyword>
  <keyword>Amylin</keyword>
  <keyword>Lilly</keyword>
  <keyword>insulin aspart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four patients withdrew from the study prior to receiving study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide Arm</title>
          <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Biphasic Insulin Aspart Arm</title>
          <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment (Intent to Treat)</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Glucose Control</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>IIT population</population>
      <group_list>
        <group group_id="B1">
          <title>Exenatide Arm</title>
          <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Biphasic Insulin Aspart Arm</title>
          <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="253"/>
            <count group_id="B2" value="248"/>
            <count group_id="B3" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="8.7"/>
                    <measurement group_id="B2" value="58.5" spread="9.2"/>
                    <measurement group_id="B3" value="58.7" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glcosylated Hemoglobin (HbA1c)</title>
        <description>Change in HbA1c from baseline to week 52</description>
        <time_frame>baseline, week 52</time_frame>
        <population>Last Observation Carried Forward; Intent to Treat, computed from the patients having both baseline and post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glcosylated Hemoglobin (HbA1c)</title>
          <description>Change in HbA1c from baseline to week 52</description>
          <population>Last Observation Carried Forward; Intent to Treat, computed from the patients having both baseline and post-baseline data.</population>
          <units>percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="0.07"/>
                    <measurement group_id="O2" value="8.65" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.07"/>
                    <measurement group_id="O2" value="-0.88" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Pre-specified non-inferiority margin was 0.4% (i.e., noninferiority is demonstrated if the upper limit of a two-sided 95% confidence interval for the difference in change in HbA1c between exenatide and biphasic insulin aspart is less than 0.4%.)</non_inferiority_desc>
            <p_value>0.2534</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c &lt;=7%</title>
        <description>Percentage of patients in each arm who had HbA1c &gt;7% at baseline and had HbA1c &lt;=7% at week 52 (percentage = [number of subjects with HbA1c &lt;=7% at week 52 divided by number of subjects with HbA1c &gt;7% at baseline] * 100%).</description>
        <time_frame>52 weeks</time_frame>
        <population>Last Observation Carried Forward; Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c &lt;=7%</title>
          <description>Percentage of patients in each arm who had HbA1c &gt;7% at baseline and had HbA1c &lt;=7% at week 52 (percentage = [number of subjects with HbA1c &lt;=7% at week 52 divided by number of subjects with HbA1c &gt;7% at baseline] * 100%).</description>
          <population>Last Observation Carried Forward; Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0779</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight from baseline to week 52.</description>
        <time_frame>baseline, week 52</time_frame>
        <population>Intent to Treat, computed from the patients having both baseline and week 52 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight from baseline to week 52.</description>
          <population>Intent to Treat, computed from the patients having both baseline and week 52 data.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline body weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.51" spread="0.99"/>
                    <measurement group_id="O2" value="83.38" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in body weight at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="0.17"/>
                    <measurement group_id="O2" value="2.92" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Glucose</title>
        <description>Change in fasting serum glucose from baseline to week 52</description>
        <time_frame>baseline, week 52</time_frame>
        <population>Intent to Treat, computed from the patients having both baseline and week 52 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Glucose</title>
          <description>Change in fasting serum glucose from baseline to week 52</description>
          <population>Intent to Treat, computed from the patients having both baseline and week 52 data.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline fasting serum glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="0.18"/>
                    <measurement group_id="O2" value="11.30" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in fasting serum glucose at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="0.19"/>
                    <measurement group_id="O2" value="-1.64" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6456</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 7-point Self-monitored Blood Glucose (SMBG) Profile</title>
        <description>Change in 7-point (pre-breakfast, after breakfast, pre-lunch, after lunch, pre-dinner, after dinner, 0300 hours) SMBG profile from baseline to week 52</description>
        <time_frame>baseline, week 52</time_frame>
        <population>Last Observation Carried Forward; Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 7-point Self-monitored Blood Glucose (SMBG) Profile</title>
          <description>Change in 7-point (pre-breakfast, after breakfast, pre-lunch, after lunch, pre-dinner, after dinner, 0300 hours) SMBG profile from baseline to week 52</description>
          <population>Last Observation Carried Forward; Intent to Treat</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-breakfast: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57" spread="2.34"/>
                    <measurement group_id="O2" value="9.86" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-breakfast: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="2.60"/>
                    <measurement group_id="O2" value="-1.68" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.30" spread="3.02"/>
                    <measurement group_id="O2" value="12.71" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="3.30"/>
                    <measurement group_id="O2" value="-3.06" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.38" spread="2.86"/>
                    <measurement group_id="O2" value="9.86" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="3.01"/>
                    <measurement group_id="O2" value="-2.40" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" spread="3.14"/>
                    <measurement group_id="O2" value="11.39" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="3.48"/>
                    <measurement group_id="O2" value="-1.76" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="2.86"/>
                    <measurement group_id="O2" value="9.57" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="3.25"/>
                    <measurement group_id="O2" value="-1.52" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="3.04"/>
                    <measurement group_id="O2" value="11.68" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="3.76"/>
                    <measurement group_id="O2" value="-2.44" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 AM: Baseline SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="2.63"/>
                    <measurement group_id="O2" value="9.58" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 AM: Change in SMBG at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="3.14"/>
                    <measurement group_id="O2" value="-1.95" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Hypoglycemic Events</title>
        <description>Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study divided by the total number of patients who particiapted in the 52 week Parent Study</description>
        <time_frame>52 weeks</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Hypoglycemic Events</title>
          <description>Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 52 week Parent Study divided by the total number of patients who particiapted in the 52 week Parent Study</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0"/>
                    <measurement group_id="O2" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7888</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rate of Hypoglycemic Events</title>
        <description>Change in rate of hypoglycemic events per 30 days per patient from baseline to week 52</description>
        <time_frame>baseline, week 52</time_frame>
        <population>Last Observation Carried Forward; Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Arm</title>
            <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Biphasic Insulin Aspart Arm</title>
            <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rate of Hypoglycemic Events</title>
          <description>Change in rate of hypoglycemic events per 30 days per patient from baseline to week 52</description>
          <population>Last Observation Carried Forward; Intent to Treat</population>
          <units>events per 30 days per patient</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline event rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.07"/>
                    <measurement group_id="O2" value="0.18" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in event rate at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.06"/>
                    <measurement group_id="O2" value="0.26" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3722</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide Arm</title>
          <description>subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Biphasic Insulin Aspart Arm</title>
          <description>subcutaneous injection, twice daily; titration to target blood glucose level</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA8.0/11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
                <counts group_id="E2" subjects_affected="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Calcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Cellulitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Injection site cellulitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Breast microcalcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA8.0/11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="179"/>
                <counts group_id="E2" subjects_affected="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

